Humira (AbbVie). The best-selling drug in history ($200B+ lifetime sales). The Drag: Patent expired in 2016 in the US. The Tactic: AbbVie filed over 250 patents on the drug. The Result: Despite the patent expiry, the first biosimilar (Amjevita) didn't launch until 2023 . The Cost: 7 years of "drag." Patients paid $38,000/year for a drug that should have cost $3,000/year. The legal strategy was so successful it is now taught in MBA schools as "The AbbVie Blueprint."
Drag Pharma's approach has several benefits that are revolutionizing the pharmaceutical industry: drag pharma
No, this isn't a new autoimmune disease. It is the silent, systemic friction that slows down the drug development pipeline—often deliberately. Humira (AbbVie)